Drugs / MK0359
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00482235 | Dec 2002 → Apr 2003 | chronic obstructive pulmonary disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00482417 | Dec 2002 → May 2003 | rheumatoid arthritis | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00482898 | Sep 2002 → Apr 2003 | asthma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-0359 | “This study evaluated the efficacy and safety of MK-0359, a selective and potent oral PDE4 inhibitor, in chronic asthma.” PMID 19135348 ↗ Jan 2009 |
| Action | Inhibit | “This study evaluated the efficacy and safety of MK-0359, a selective and potent oral PDE4 inhibitor, in chronic asthma.” PMID 19135348 ↗ Jan 2009 |
| Route | Oral | “MK-0359, a selective and potent oral PDE4 inhibitor” PMID 19135348 ↗ Jan 2009 |